309 Results
Sort By:
Published on May 8, 2024
Scientists at Scripps Research have discovered a technique for boosting T cells’ ability to recognize and kill solid tumor cells. By removing a sugar present on the exterior of solid tumor cancer cells, T cells can move closer to their target. Studies in mice showed that the enhanced proximity of…
Published on April 25, 2024
Researchers at the Technical University of Munich (TUM) and the Ludwig Maximilian University (LMU) Hospital Munich have discovered a mechanism by which tumor cells can prevent an immune response by cytotoxic T cells. It is widely known that certain tumors are capable of tricking the immune system, thereby allowing the…
Published on April 17, 2024
Scientists are seeking new ways to develop immunotherapies with different targets especially for patients with these cancers don’t respond to immune checkpoint inhibitors. Now, researchers from Osaka University report that tetracycline antibiotics help the immune system find cancer cells in a way that is different from current immunotherapies. The researchers…
Published on May 10, 2023
Researchers at the University of Pittsburgh have developed a universal receptor system that allows T cells to recognize any cell surface target, providing the possibility for tailored CAR T cell and other immunotherapies used to treat diseases such as cancer. T cell therapies, especially those involving CAR T cells are…
Published on December 16, 2022
Despite significant advances in breast cancer treatment, tumors that don’t respond to hormone therapy, targeted drugs, or chemotherapy, remain hard to treat. Tulane University researchers have now determined how these cancers persist after chemo and why they don’t respond well to immunotherapies. According to their study, published in Nature Cancer,…
Published on October 27, 2022
U.K. startup VacV Biotherapeutics has emerged from stealth mode as it stands poised to bring its novel viral-based cancer therapies into clinical development. The spin out from Barts Cancer Institute and Queen Mary University of London uses immunotherapy based on a genetically modified version of the Vaccinia virus to stimulate…
Published on June 24, 2021
Advances in Cell Immunotherapies in Treating Cancer
Published on March 8, 2021
Brain metastases are the most common tumor of the brain with a very poor prognosis. A fraction of patients with brain metastasis benefit from treatment with immune checkpoint inhibitors like anti-PD1, anti-PD-L1, and anti-CTLA4 drugs. One of the limitations of these drugs over the long-term in brain tumors is that…
Published on April 15, 2019
Using miniature laboratory-grown tumors known as patient-derived organoids (PDOs) as models of colorectal cancer (CRC), researchers at The Institute of Cancer Research and the Royal Marsden NHS Foundation Trust in the U.K. have found that CRC tumors can switch off expression of a cell surface molecule that is a key…
Published on November 3, 2017
Epic Sciences said it will add simultaneous microsatellite instability (MSI) and chromosomal instability (CIN) measurements—also called genomic scarring analysis—to its single cell next generation sequencing (NGS) workflow for clinical research of immuno-oncology therapies. Epic is looking to combine the MSI and CIN capabilities at a time when researchers have reported…
Published on September 7, 2016
The principle underlying molecular diagnostics is simple—devise a methodology that quickly detects an altered state through the analysis of a biological marker. With that philosophy in mind, companies go to great lengths to develop sophisticated equipment that will accurately measure either a single or collection of biomarkers that are known…
Published on May 29, 2024
Researchers at the University College London (UCL) and UCL Great Ormond Street Institute of Child Health have developed a novel immunotherapeutic platform technology that uses engineered T cells to attack bone cancer cells and activate other cancer-fighting immune cells to do the same. The researchers aimed to overcome different challenges…
Published on May 22, 2024
A preclinical study by Cleveland Clinic researchers reveals that the immune checkpoint protein VISTA can turn off tumor-fighting T cells during immunotherapy and resist treatment. The work using mouse models, showed that VISTA can bind to a protein called LRIG1 in T cells, which was previously only thought to promote…
Published on May 8, 2024
A mechanism by which natural killer (NK) cells impede immune checkpoint inhibitors (ICIs) in cancer treatment has been uncovered by researchers from the German Cancer Research Center (DKFZ) and the University Medical Center Mannheim (UMM). The team found that the immunoglobulin superfamily ligand B7H6 promotes cytolysis of activated T cells…
Published on May 1, 2024
Researchers at the University of Florida report they have developed an mRNA cancer vaccine that quickly reprograms the immune system to attack glioblastoma in a first-ever human clinical trial of four adult patients. Their results published in Cell mirror those from preclinical mouse studies, and from a newly reported trial…